HUMANIZED ANTI-IGF-I RECEPTOR ANTIBODY
MX434327BActive Publication Date: 2026-05-19TEIJIN PHARMA CO LTD
Patent Information
- Authority / Receiving Office
- MX · MX
- Patent Type
- Patents
- Current Assignee / Owner
- TEIJIN PHARMA CO LTD
- Filing Date
- 2021-06-01
- Publication Date
- 2026-05-19
AI Technical Summary
Technical Problem
Current treatments for diseases associated with IGF-I receptor, such as muscle atrophy and dwarfism, face challenges due to the hypoglycemic effects and short half-life of IGF-I, which require frequent administrations and can cause adverse reactions like hyperglycemia.
Method used
Development of a humanized anti-IGF-I receptor antibody that specifically binds to the IGF-I receptor, increasing muscle mass without reducing blood glucose levels and having a longer half-life, allowing for less frequent dosing.
Benefits of technology
The antibody effectively induces muscle growth and prolongs the duration of action, overcoming the limitations of IGF-I by maintaining stable glucose levels and reducing the frequency of administration.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to a humanized antibody that, through the IGF-I receptor, increases muscle mass but does not reduce blood glucose levels. This humanized antibody: is a humanized anti-IGF-I receptor antibody, a fragment thereof, or a derivative thereof; has a specific amino acid sequence such as SEQ ID NOs: 1 to 6 that serve as a CDR sequence; and binds specifically to the extracellular domain of the IGF-I receptor.
Need to check novelty before this filing date? Find Prior Art